Novartis AG (NVS) Given Consensus Rating of “Hold” by Brokerages

Novartis AG (NYSE:NVS) has been assigned an average recommendation of “Hold” from the eighteen analysts that are presently covering the firm, MarketBeat.com reports. Five research analysts have rated the stock with a sell rating, six have given a hold rating, six have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $87.57.

Several research firms have recently weighed in on NVS. Zacks Investment Research cut shares of Novartis from a “hold” rating to a “strong sell” rating in a report on Thursday, April 11th. Morgan Stanley cut shares of Novartis from an “equal weight” rating to an “underweight” rating and upped their price target for the company from $82.50 to $82.52 in a report on Wednesday, April 10th. JPMorgan Chase & Co. reiterated a “sell” rating on shares of Novartis in a report on Tuesday, January 29th. Finally, Credit Suisse Group cut shares of Novartis to a “sell” rating in a report on Thursday, December 20th.

In other news, major shareholder Bioventures Ltd Novartis sold 28,794 shares of the company’s stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $0.99, for a total value of $28,506.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 870,195 shares of company stock valued at $1,062,051 in the last quarter. Corporate insiders own 0.01% of the company’s stock.

Hedge funds have recently made changes to their positions in the company. Truvestments Capital LLC bought a new stake in Novartis during the first quarter worth $25,000. Canton Hathaway LLC acquired a new position in shares of Novartis in the first quarter valued at $26,000. AlphaMark Advisors LLC acquired a new position in shares of Novartis in the fourth quarter valued at $30,000. Legacy Advisors LLC acquired a new position in shares of Novartis in the first quarter valued at $38,000. Finally, Laurel Wealth Advisors LLC acquired a new position in shares of Novartis in the fourth quarter valued at $35,000. 11.68% of the stock is currently owned by institutional investors and hedge funds.

NYSE NVS traded down $0.47 during trading on Tuesday, reaching $80.49. 27,119 shares of the stock traded hands, compared to its average volume of 2,880,435. The stock has a market cap of $187.02 billion, a P/E ratio of 15.84, a P/E/G ratio of 2.06 and a beta of 0.68. The company has a debt-to-equity ratio of 0.29, a quick ratio of 0.97 and a current ratio of 1.20. Novartis has a fifty-two week low of $72.30 and a fifty-two week high of $96.31.

Novartis (NYSE:NVS) last issued its quarterly earnings data on Wednesday, January 30th. The company reported $1.24 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.33 by ($0.09). The firm had revenue of $13.27 billion for the quarter, compared to analyst estimates of $13.33 billion. Novartis had a net margin of 24.30% and a return on equity of 15.66%. The firm’s revenue for the quarter was up 2.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.21 EPS. Analysts predict that Novartis will post 5.1 earnings per share for the current fiscal year.

Novartis Company Profile

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products.

Featured Article: Are FAANG stocks a good investment?

Analyst Recommendations for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit